指南与共识其他结缔组织病

以目标为导向治疗幼年皮肌炎:欧洲儿科风湿病学会/儿童关节炎和风湿病研究联盟认可的国际工作组建议

Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force.
指南 / 共识 · Ann Rheum Dis · 2025-05-22

该建议由国际工作组基于系统文献综述和回顾性病历审查制定,达成7项总体原则和12条推荐,提出以无活动性疾病为首选目标、轻微疾病活动为替代目标,目标在治疗开始后12个月内实现,并建议12个月内逐步减停糖皮质激素。

要点

  • 首选治疗目标为无活动性疾病,替代目标为轻微疾病活动,目标在治疗开始后12个月内实现。
  • interim目标包括6周内轻微临床改善、3个月内中度临床改善、6个月内肌力正常化。
  • 大剂量糖皮质激素仍是初始治疗基础,建议通过优化联合免疫调节治疗在12个月内逐步减停。

核心结论

  • 工作组制定了以目标为导向治疗幼年皮肌炎的建议,并认识到证据不充分,需未来研究扩展。
  • 在临床实践中实施这些建议将有助于幼年皮肌炎患者达到最佳结局。

研究设计与样本

  • 指导委员会基于系统文献综述和患者回顾性病历审查制定临时建议,由国际工作组讨论、修订并投票,工作组包括28名儿科风湿病学家、2名神经肌肉疾病专家、1名皮肤科医生、1名物理治疗师、1名研究护士、2名幼年皮肌炎患者和1名患者家长,获得至少80%多数票的项目被接受为最终建议。

主要发现

  • 文献综述未发现比较以目标为导向策略与非导向方法的试验,但提供了关于可作为目标的特定终点的间接证据。
  • 工作组就7项总体原则和12条推荐达成共识。

关键数值与推荐

  • 患者/家长与治疗者应共同决策设定治疗目标和治疗策略,首选目标为无活动性疾病,替代目标为轻微疾病活动。
  • 无活动性疾病的目标是在治疗开始后12个月内实现。
  • interim目标包括6周内轻微临床改善、3个月内中度临床改善、6个月内肌力正常化。
  • 大剂量糖皮质激素仍是初始治疗的基础,但建议通过优化联合免疫调节治疗在12个月内逐步减停。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据不充分,需未来研究扩展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite the recent prognostic improvement, a sizeable proportion of patients with juvenile dermatomyositis (JDM) respond suboptimally to contemporary therapies. This study aimed to develop recommendations for treating JDM to target. METHODS: A Steering Committee formulated a set of provisional recommendations based on evidence derived from a systematic literature review and a retrospective chart review of patients. These were discussed, amended, and voted on by an international Task Force, including 28 paediatric rheumatologists, 2 specialists in neuromuscular diseases, 1 dermatologist, 1 physical therapist, 1 research nurse, 2 patients with JDM, and 1 parent of a patient with JDM. Items that achieved at least an 80% majority vote were accepted as final recommendations. RESULTS: Although the literature review did not reveal trials that compared a treat-to-target strategy with a nonsteered approach, it provided indirect evidence about specific end points that could serve as targets that facilitated development of recommendations. The group reached consensus on 7 overarching principles and 12 recommendations. It was agreed that both patients/parents and treaters should share decisions in setting treatment targets and therapeutic strategies, with inactive disease as the preferred target and minimal disease activity an alternative one. Inactive disease is targeted to be achieved within 12 months after treatment start. Interim targets include minimal and moderate clinical improvement within 6 weeks and 3 months, respectively, and normalisation of muscle strength within 6 months. High-dose glucocorticoids remain fundamental in the initial management, but progressive tapering and discontinuation within 12 months through optimisation of concomitant immunomodulatory therapy was advised. A research agenda was formulated. CONCLUSIONS: The Task Force developed recommendations for treating JDM to target, being aware that the evidence is not strong and needs to be expanded by future research. Implementation of the recommendations in clinical practice will help to reach optimal outcomes for JDM.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ravelli A, Rosina S, MacMahon JM, et al. Treating juvenile dermatomyositis to target: Paediatric Rheumatology European Society/Childhood Arthritis and Rheumatology Research Alliance-endorsed recommendations from an international task force. Ann Rheum Dis. 2025. PMID: 40410052. doi:10.1016/j.ard.2025.04.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。